Organigram Holdings Inc. is a Canadian licensed producer of cannabis, focused on the development and cultivation of high-quality marijuana products for both medical and recreational markets
The company operates state-of-the-art facilities that utilize advanced technology and sustainable practices to grow and produce a variety of cannabis strains, including dried flower and cannabis oils. Organigram is committed to innovation in product development, creating a wide range of cannabis-infused products such as edibles, beverages, and vape oils. With a strong emphasis on compliance, quality control, and consumer education, Organigram aims to be a leading player in the evolving cannabis industry while promoting responsible use and supporting community initiatives.
Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its first quarter fiscal 2025 ended December 31, 2024, on Tuesday, February 11, 2025, prior to market open.
DEA judge orders agency to respond to allegations of opposing marijuana rescheduling and improper communication with opponents. Cannabis stocks declined in 2024 due to concerns about DEA review.
This earnings release replaces the previously filed earnings release on December 18, 2024 to correct errors in the outstanding share data tables under the heading “CAPITAL STRUCTURE.” No other changes are being made. The Company is also refiling its Management’s Discussion and Analysis for the twelve months ended September 30, 2024 to correct corresponding errors in the outstanding share data table, which corrections will also apply to the MD&A included in the Company’s Annual Report filed on December 18, 2024.
Organigram's Q4 sales hit $31.22 million, boosted by recreational and international growth, with adjusted gross margin improving to 37% of net revenue.
Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its fourth quarter and fiscal 2024 ended September 30, 2024, on Wednesday, December 18, 2024, prior to market open.
Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI) has announced the acquisition of 100% of Motif Labs Ltd. for CA$90 million ($64 million), comprising of CA$50 million in cash and CA$40 million in Organigram common shares, based on a 30-day trading VWAP of $2.321 on the TSX. An additional CA$10 million contingent consideration is payable in shares, conditional on achieving a share price above $3.2203 within 12 months. The deal is financed through Organigram's cash reserves.
Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce the acquisition of 100% of the issued and outstanding shares of Motif Labs Ltd. (“Motif”), for upfront consideration of $90 million, consisting of $50 million in cash and $40 million of Organigram common shares priced based on the 30 day trading VWAP of $2.3210 on the Toronto Stock Exchange (“TSX”). In addition, Motif shareholders will be entitled to receive additional contingent consideration of $10 million payable in Organigram common shares (“Contingent Consideration”), conditional on Organigram achieving a price per share exceeding $3.2203 per share, based on the rolling 30-trading day VWAP on the TSX, within 12 months of the date of the transaction. The Contingent Consideration shall be priced at of $3.22031 per share.
Organigram Holdings Inc. (NASDAQOGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is thrilled to finally launch Edison Sonics gummies, Organigram’s inaugural product powered by FAST™, the Company’s groundbreaking nanoemulsion technology and a first-to-market innovation.
Our Conservative Cannabis Stocks Portfolio has outperformed our Canadian Cannabis LP Stocks Portfolio by more than a 3 to 1 margin on an annual basis. As such, our conservative cannabis portfolio is just that - a conservative cannabis investment.
The Canadian Cannabis LP Stocks Portfolio was up +6% last week from a 10% decline w/e Sept. 6th as the negative sentiment waned surrounding the DEA's announcement that it would be having a December 2nd hearing to consider additional opinions
